Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Immunic, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 VIDOFLUDIMUS CALCIUM SUBSTANTIALLY REDUCED 24-WEEK CONFIRMED DISABILITY WORSENING IN PHASE 2 CALLIPER TRIAL IN OVERALL PROGRESSIVE MULTIPLE SCLEROSIS STUDY POPULATION AND ACROSS SUBTYPES,REINFORCING THE DRUG'S NEUROPROTECTIVE POTENTIAL AND ABILITY TO SLOW DISEASE PROGRESSION   COMPLETED ENROLLMENT FOR BOTH PHASE 3 ENSURE TRIALS OF VIDOFLUDIMUS CALCIUM IN RELAPSING MULTIPLE SCLEROSIS; TOP-LINE DATA EXPECTED BY END OF 2026   NEW LONG-TERM OPEN-LABEL EXTENSION DATA FROM PHASE 2 EMPHASIS TRIAL IN RELAPSING-REMITTING MULTIPLE SCLEROSIS SHOWED HIGH RATES OF PATIENTS REMAINING FREE OF 12-WEEK AND 24-WEEK CONFIRMED DISABILITY WORSENING   STRENGTHENED BALANCE SHEET WITH TWO FINANCINGS TOTALING $70.1 MILLION IN GROSS PROCEEDS  NEW YORK , AUG. 7, 2025 /PRNEWSWIRE/ -- IMMUNIC, INC. (NASDAQ: IMUX),A BIOTECHNOLOGY COMPANY DEVELOPING A CLINICAL PIPELINE OF ORALLY ADMINISTERED, SMALL MOLECULE THERAPIES FOR CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE. "DURING THE SECOND QUARTER AND MORE RECENTLY, WE HAVE MADE SUBSTANTIAL CLINICAL PROGRESS IN ADVANCING OUR POTENTIALLY TRANSFORMATIVE LEAD ASSET, VIDOFLUDIMUS CALCIUM (IMU-838), AN ORALLY AVAILABLE NUCLEAR RECEPTOR-RELATED 1 (NURR1) ACTIVATOR," STATED DANIEL VITT, PH.D.

IMMUNIC, INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

 AT WEEK 144, 92.3% OF PATIENTS REMAINED FREE OF 12-WEEK CONFIRMED DISABILITY WORSENING (CDW) WITH 92.7% REMAINING FREE OF 24-WEEK CDW   VIDOFLUDIMUS CALCIUM CONTINUES TO DEMONSTRATE FAVORABLE SAFETY AND TOLERABILITY PROFILE; LONG-TERM DATA NOW AVAILABLE UP TO 5.5 YEARS  NEW YORK , JUNE 24, 2025 /PRNEWSWIRE/ -- IMMUNIC, INC. (NASDAQ: IMUX),A BIOTECHNOLOGY COMPANY DEVELOPING A CLINICAL PIPELINE OF ORALLY ADMINISTERED, SMALL MOLECULE THERAPIES FOR CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES, TODAY REPORTED NEW LONG-TERM OPEN-LABEL EXTENSION (OLE) DATA FROM ITS PHASE 2 EMPHASIS TRIAL OF LEAD ASSET,ORALLY AVAILABLE NUCLEAR RECEPTOR-RELATED 1 (NURR1) ACTIVATOR, VIDOFLUDIMUS CALCIUM (IMU-838), IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS). "IT IS MEANINGFUL TO SEE THAT PATIENTS TREATED WITH VIDOFLUDIMUS CALCIUM DURING THE OLE PERIOD OF OUR PHASE 2 EMPHASIS TRIAL IN RRMS EXPERIENCEDA LOW RATE OF CONFIRMED DISABILITY WORSENING (CDW) EVENTS, AS MEASURED BY THE EXPANDED DISABILITY STATUS SCALE (EDSS).

IMMUNIC REPORTS NEW, POSITIVE LONG-TERM OPEN-LABEL EXTENSION DATA FROM PHASE 2 EMPHASIS TRIAL OF VIDOFLUDIMUS CALCIUM IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

 ENROLLMENT COMPLETED FOR BOTH PHASE 3 ENSURE TRIALS OF VIDOFLUDIMUS CALCIUM IN RELAPSING MULTIPLE SCLEROSIS; TOP-LINE DATA EXPECTED END OF 2026   ADDITIONAL DATA FROM PHASE 2 CALLIPER TRIAL IN PROGRESSIVE MULTIPLE SCLEROSIS FURTHER SUPPORTS THE RECENTLY RELEASED POSITIVE TOP-LINE RESULTS AND FURTHER UNDERLINES VIDOFLUDIMUS CALCIUM'S NEUROPROTECTIVE POTENTIAL   NEW CALLIPER DATA REGARDING TIME TO 24-WEEK CONFIRMED DISABILITY WORSENING SHOWS SUBSTANTIAL AND MEDICALLY RELEVANT REDUCTIONS FOR VIDOFLUDIMUS CALCIUM OVER PLACEBO IN THE OVERALL STUDY POPULATION AND MAJOR DISEASE SUBTYPES  NEW YORK , JUNE 5, 2025 /PRNEWSWIRE/ -- IMMUNIC, INC. (NASDAQ: IMUX),A BIOTECHNOLOGY COMPANY DEVELOPING A CLINICAL PIPELINE OF ORALLY ADMINISTERED, SMALL MOLECULE THERAPIES FOR CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES, ANNOUNCED THE COMPLETION OF ENROLLMENT FOR BOTH PHASE 3 ENSURE TRIALS OF LEAD ASSET, NUCLEAR RECEPTOR-RELATED 1 (NURR1) ACTIVATOR, VIDOFLUDIMUS CALCIUM (IMU-838), IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS AND ADDITIONAL PHASE 2 CALLIPER TRIAL DATA IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS UNDERLINING THE RECENTLY RELEASED POSITIVE TOP-LINE RESULTS. ENROLLMENT COMPLETED FOR BOTH PHASE 3 ENSURE TRIALS IN RELAPSING MULTIPLE SCLEROSIS (RMS) THE ENSURE PROGRAM COMPRISES TWO IDENTICAL MULTICENTER, RANDOMIZED, DOUBLE-BLIND PHASE 3 TRIALS DESIGNED TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF VIDOFLUDIMUS CALCIUM VERSUS PLACEBO IN RMS PATIENTS.

IMMUNIC ANNOUNCES COMPLETION OF ENROLLMENT FOR BOTH PHASE 3 ENSURE TRIALS IN RELAPSING MS AND PRESENTS ADDITIONAL DATA UNDERLINING POSITIVE OUTCOME OF PHASE 2 CALLIPER TRIAL IN PROGRESSIVE MS

NEW YORK , JUNE 3, 2025 /PRNEWSWIRE/ -- IMMUNIC, INC. ("IMMUNIC" OR THE "COMPANY") (NASDAQ: IMUX), A BIOTECHNOLOGY COMPANY DEVELOPING A CLINICAL PIPELINE OF ORALLY ADMINISTERED, SMALL MOLECULE THERAPIES FOR CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF (I) PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK (THE "PRE-FUNDED WARRANTS"), (II) SERIES A WARRANTS TO PURCHASE SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS) (THE "SERIES A WARRANTS"), AND (III) SERIES B WARRANTS TO PURCHASE SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS) (THE "SERIES B WARRANTS"). THE PRE-FUNDED WARRANTS ARE IMMEDIATELY EXERCISABLE, AND MAY BE EXERCISED AT ANY TIME AFTER THEIR ORIGINAL ISSUANCE.

IMMUNIC, INC. ANNOUNCES CLOSING OF OVERSUBSCRIBED $65 MILLION UNDERWRITTEN PUBLIC OFFERING

NEW YORK , JUNE 2, 2025 /PRNEWSWIRE/ -- IMMUNIC, INC. (NASDAQ: IMUX),A BIOTECHNOLOGY COMPANY DEVELOPING A CLINICAL PIPELINE OF ORALLY ADMINISTERED, SMALL MOLECULE THERAPIES FOR CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED PARTICIPATION IN THE FOLLOWING INVESTOR, SCIENTIFIC AND INDUSTRY CONFERENCES IN JUNE: JUNE 3-5:JEFFERIES HEALTHCARE CONFERENCE. DANIEL VITT, PH.D.

IMMUNIC TO PARTICIPATE IN INVESTOR, SCIENTIFIC AND INDUSTRY CONFERENCES IN JUNE

NEW YORK , MAY 29, 2025 /PRNEWSWIRE/ -- IMMUNIC, INC. ("IMMUNIC" OR THE "COMPANY") (NASDAQ: IMUX), A BIOTECHNOLOGY COMPANY DEVELOPING A CLINICAL PIPELINE OF ORALLY ADMINISTERED, SMALL MOLECULE THERAPIES FOR CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF (I) PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK (THE "PRE-FUNDED WARRANTS"), (II) SERIES A WARRANTS TO PURCHASE SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS) (THE "SERIES A WARRANTS"), AND (III) SERIES B WARRANTS TO PURCHASE SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS) (THE "SERIES B WARRANTS"). THE COMBINED PUBLIC OFFERING PRICE OF ONE PRE-FUNDED WARRANT, ONE SERIES A WARRANT, AND ONE SERIES B WARRANT, WHICH ARE BEING SOLD TOGETHER BUT ARE IMMEDIATELY SEPERABLE, IS $0.7499.

IMMUNIC, INC. ANNOUNCES PRICING OF OVERSUBSCRIBED $65 MILLION UNDERWRITTEN PUBLIC OFFERING

NEW YORK , MAY 28, 2025 /PRNEWSWIRE/ -- IMMUNIC, INC. ("IMMUNIC" OR THE "COMPANY") (NASDAQ: IMUX), A BIOTECHNOLOGY COMPANY DEVELOPING A CLINICAL PIPELINE OF ORALLY ADMINISTERED, SMALL MOLECULE THERAPIES FOR CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF (I) PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK, (II) SERIES A WARRANTS TO PURCHASE SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS) EXPIRING ON DECEMBER 31, 2025, (III) AND SERIES B WARRANTS TO PURCHASE SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS) EXPIRING FIVE YEARS FOLLOWING THE ISSUANCE DATE. THE SERIES A AND B WARRANTS WILLIMMEDIATELYEXPIRE INPROPORTIONTOTHEEXTENT THATTHE CORRESPONDINGPRE-FUNDEDWARRANTOFFEREDHEREBY ISEXERCISEDONORPRIOR TOSEPTEMBER30,2025, SUBJECT TO CERTAIN EXCEPTIONS.

IMMUNIC, INC. ANNOUNCES PROPOSED PUBLIC OFFERING

NEW YORK , MAY 2, 2025 /PRNEWSWIRE/ -- IMMUNIC, INC. (NASDAQ: IMUX),A BIOTECHNOLOGY COMPANY DEVELOPING A CLINICAL PIPELINE OF ORALLY ADMINISTERED, SMALL MOLECULE THERAPIES FOR CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED PARTICIPATION IN THE FOLLOWING SCIENTIFIC AND INDUSTRY CONFERENCES IN MAY: MAY 3-6:DIGESTIVE DISEASE WEEK (DDW). TWO ABSTRACTS DISCUSSING IMMUNIC'S PHASE 1/1B CLINICAL TRIAL OF IMU-856, AN ORALLY AVAILABLE AND SYSTEMICALLY ACTING SMALL MOLECULE MODULATOR THAT TARGETS SIRT6 (SIRTUIN 6), IN PATIENTS WITH CELIAC DISEASE, HAVE BEEN ACCEPTED FOR POSTER PRESENTATIONS AT THIS CONFERENCE INSAN DIEGO, CA.

IMMUNIC TO PARTICIPATE IN SCIENTIFIC AND INDUSTRY CONFERENCES IN MAY

 REDUCED RELATIVE RISK OF 24-WEEK CONFIRMED DISABILITY WORSENING EVENTS BY 20% IN OVERALL STUDY POPULATION COMPARED TO PLACEBO; EVEN MORE PROMINENT 30% REDUCTION IN HIGH UNMET NEED POPULATION OF PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS   SHOWED CONSISTENT REDUCTION OF DISABILITY WORSENING IN SUBPOPULATIONS WITHOUT INFLAMMATORY LESIONS AT BASELINE IN OVERALL STUDY POPULATION; REDUCED RELATIVE RISK OF 24-WEEK CONFIRMED DISABILITY WORSENING EVENTS IN PATIENTS WITHOUT GADOLINIUM-ENHANCING LESIONS AT BASELINE BY 29% COMPARED TO PLACEBO   REDUCED ANNUALIZED RATE OF THALAMIC BRAIN VOLUME LOSS BY 20% COMPARED TO PLACEBO   CONFIRMED FAVORABLE SAFETY AND TOLERABILITY OBSERVED IN PREVIOUS CLINICAL TRIALS; NO NEW SAFETY SIGNALS IDENTIFIED   WEBCAST TO BE HELD TODAY, APRIL 30, AT 8:00 AM ET  NEW YORK , APRIL 30, 2025 /PRNEWSWIRE/ -- IMMUNIC, INC. (NASDAQ: IMUX), A BIOTECHNOLOGY COMPANY DEVELOPING A CLINICAL PIPELINE OF ORALLY ADMINISTERED, SMALL MOLECULE THERAPIES FOR CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED POSITIVE DATA FROM ITS PHASE 2 CALLIPER TRIAL OF NUCLEAR RECEPTOR RELATED 1 (NURR1) ACTIVATOR, VIDOFLUDIMUS CALCIUM (IMU-838), IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS (PMS). CLINICAL ENDPOINTS IN THE OVERALL PMS PATIENT POPULATION (N=467), VIDOFLUDIMUS CALCIUM REDUCED THE RELATIVE RISK OF 24-WEEK CONFIRMED DISABILITY WORSENING (24WCDW) EVENTS BASED ON CHANGES IN THE EXPANDED DISABILITY STATUS SCALE (EDSS) BY 20% COMPARED TO PLACEBO.

IMMUNIC ANNOUNCES VIDOFLUDIMUS CALCIUM REDUCED RISK OF DISABILITY WORSENING BY 30% IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS PATIENTS FROM PHASE 2 CALLIPER TRIAL

NEW YORK , APRIL 10, 2025 /PRNEWSWIRE/ --IMMUNIC, INC. ("IMMUNIC" OR THE "COMPANY") (NASDAQ: IMUX), A BIOTECHNOLOGY COMPANY DEVELOPING A CLINICAL PIPELINE OF ORALLY ADMINISTERED, SMALL MOLECULE THERAPIES FOR CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED REGISTERED DIRECT OFFERING OF 5,666,667 SHARES OF ITS COMMON STOCK AT A PRICE OF $0.90 PER SHARE, LED BY ABERDEEN INVESTMENTS. ALL SECURITIES IN THE OFFERING WERE SOLD BY IMMUNIC.

Immunic, Inc.

IMUX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Immunic, Inc.

IMUX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMUX